Brilinta Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge
By
Sue Sutter / Email the Author / Pharmaceutical Approvals Monthly January 2012, Vol. 17, No. 1
Drug Review Profile / Word Count: 1738 / Article # 06120101001
Executive Summary
The ticagrelor NDA ignited strong opinions from the cross-discipline team leader about sponsor AstraZeneca’s conduct, drawing a forceful response from the review division director.
$85.00
Buy Now
For $85.00, purchase this 1738-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.